Matches in Wikidata for { <http://www.wikidata.org/entity/Q62062590> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q62062590 description "clinical trial" @default.
- Q62062590 description "ensayu clínicu" @default.
- Q62062590 description "klinisch onderzoek" @default.
- Q62062590 description "клінічне випробування" @default.
- Q62062590 description "临床试验" @default.
- Q62062590 name "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q62062590 type Item @default.
- Q62062590 label "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q62062590 prefLabel "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q62062590 P1050 Q62062590-012D4C7D-2E51-40D2-9360-8FCE8A962799 @default.
- Q62062590 P1050 Q62062590-1F6069A2-6F6E-4DC6-BEB8-F091CE4CA7D8 @default.
- Q62062590 P1050 Q62062590-F6D7C90F-61AD-4487-A2F9-DCF3ACEBFC1E @default.
- Q62062590 P1132 Q62062590-01C426C2-618A-4AD9-9F17-643603B03091 @default.
- Q62062590 P1476 Q62062590-E72DDA75-FF7A-4215-B852-D645AED3F29F @default.
- Q62062590 P17 Q62062590-0DFF8187-B2EE-4426-9027-289F6D9FEEA5 @default.
- Q62062590 P2899 Q62062590-0D82A5F4-CC3B-4F61-9A81-B7E169302EF3 @default.
- Q62062590 P3098 Q62062590-DB7D4471-0A99-43E8-BBDD-13A2E53A1D08 @default.
- Q62062590 P31 Q62062590-A22598D4-B0D3-4BEE-B810-60C6C142FD2E @default.
- Q62062590 P4135 Q62062590-C0F773E8-6BBE-439A-9B53-94DC57510883 @default.
- Q62062590 P4844 Q62062590-4C4C6B29-901B-4241-966D-880F018038D9 @default.
- Q62062590 P4844 Q62062590-547E5766-0EAE-421A-B646-759BEE37F5C0 @default.
- Q62062590 P580 Q62062590-4639386E-31B8-4CE4-8CF6-4FF69D1A22C3 @default.
- Q62062590 P582 Q62062590-58863F30-D366-4B36-849D-BF50732A33B6 @default.
- Q62062590 P6099 Q62062590-A1B08FB2-0A88-47D0-A3D7-5EA224086340 @default.
- Q62062590 P8005 Q62062590-A016E67A-2DF2-4B3F-A865-EE2CDF7C7DD3 @default.
- Q62062590 P8363 Q62062590-8461B5B6-100C-44C4-973D-8D025ED9D70C @default.
- Q62062590 P1050 Q159701 @default.
- Q62062590 P1050 Q41861 @default.
- Q62062590 P1050 Q9294051 @default.
- Q62062590 P1132 "+550" @default.
- Q62062590 P1476 "A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension" @default.
- Q62062590 P17 Q30 @default.
- Q62062590 P2899 "+18" @default.
- Q62062590 P3098 "NCT03657797" @default.
- Q62062590 P31 Q30612 @default.
- Q62062590 P4135 "+85" @default.
- Q62062590 P4844 Q552308 @default.
- Q62062590 P4844 Q634959 @default.
- Q62062590 P580 "2018-08-01T00:00:00Z" @default.
- Q62062590 P582 "2019-12-01T00:00:00Z" @default.
- Q62062590 P6099 Q42824440 @default.
- Q62062590 P8005 Q76651189 @default.
- Q62062590 P8363 Q78089383 @default.